CSL Seqirus has officially opened a new $1 billion vaccine and antivenom manufacturing facility in Melbourne, Australia. This state-of-the-art facility significantly advances Australia's onshore vaccine manufacturing capabilities. The opening was marked by the presence of The Hon Mark Butler MP, Minister for Health, Disability and Ageing, highlighting its national importance.
The opening of this major $1 billion facility significantly boosts Australia's sovereign manufacturing capacity for critical vaccines and antivenoms. This reduces reliance on international supply chains, enhances national biosecurity, and positions CSL Seqirus as a key player in regional and global health security, potentially impacting market dynamics for these essential products.
$1 billion vaccine and antivenom facility opens in Melbourne.
Enhances Australia's onshore manufacturing capabilities.
Reduces reliance on international supply chains.
This facility is located in Melbourne, Australia, and is a significant development for the country's biopharmaceutical manufacturing sector and public health infrastructure.
Reduces reliance on international supply chains.
Key development for national biosecurity.
Sign in to save notes on signals.
Sign In